STOCK TITAN

Director reports multiple Class A share sales — RXRX (NASDAQ: RXRX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

RXRX filed a Form 144 reporting proposed sales of Class A founder shares.

The filing lists four sales of 40,000 Class A shares on 01/05/2026, 01/20/2026, 02/04/2026, and 02/19/2026 with proceeds of $170,000, $178,800, $164,800, and $138,400, respectively.

Positive

  • None.

Negative

  • None.

Insights

Form 144 lists four discrete sales of Class A founder shares totaling 160,000 shares across January–February 2026.

The filing identifies four transactions of 40,000 Class A shares each on 01/05/2026, 01/20/2026, 02/04/2026, and 02/19/2026, with reported gross proceeds per trade shown in the filing.

These notices are procedural disclosures required under rule 144; cash‑flow treatment and whether sales were open‑market or private are not stated in the provided excerpt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did RXRX report in this Form 144?

The filing reports four proposed sales of 40,000 Class A shares each on specific dates in Jan–Feb 2026, with reported proceeds of $170,000, $178,800, $164,800, and $138,400.

Who is the reported seller in the RXRX Form 144?

The filing names Christopher C. Gibson as the address-associated reporting person linked to the Class A share sales on the listed dates. The excerpt does not specify any additional sellers or entities.

How many shares are involved in the RXRX filing?

The filing shows four transactions of 40,000 Class A shares each, totaling 160,000 shares across the listed dates in January and February 2026 as reported in the excerpt.

Do the Form 144 entries state how the shares were sold?

The excerpt lists sale dates, share counts, and proceeds but does not describe the method of sale; the form does not state whether transactions were open-market, block trades, or privately negotiated in the provided text.
Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

View RXRX Stock Overview

RXRX Rankings

RXRX Latest News

RXRX Latest SEC Filings

RXRX Stock Data

1.72B
507.21M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SALT LAKE CITY